From Analysis:
The abstract challenges the rationale for using microtubule-stabilizing drugs in tau diseases, since tau appears to destabilize rather than stabilize microtubules. This paradigm shift has immediate implications for therapeutic development but requires validation. Gap type: open_question Source paper: Tau: It's Not What You Think. (2019, Trends Cell Biol, PMID:30929793)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Dual Leucine Zipper Kinase (DLK/MAP3K12) inhibition blocks the downstream neurotoxicity cascade triggered by wild-type tau pathology, bypassing upstream microtubule dynamics complexity. DLK activates JNK/cJun signaling coupled with DNA damage response, representing a tractable downstream intervention.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.616 | ▼ 8.0% | evidence_update | 2026-04-15 19:34 |
| 📄 | New Evidence | $0.670 | ▲ 9.8% | evidence_update | 2026-04-15 19:34 |
| ✨ | Listed | $0.610 | post_process | 2026-04-15 19:34 |
No clinical trials data available
neurodegeneration | 2026-04-15 | completed